Scott Charles - Aralez Pharmaceuticals CFO, Senior Vice President

President

Mr. Scott J. Charles is Chief Financial Officer, Senior Vice President of the Company, since February 5, 2016 since 2016.
Age 40
Tenure 8 years
Phone905-876-1118
Webhttp://www.aralez.com
Charles was previously Chief Financial Officer of Pozen from January 1, 2016 through February 5, 2016, and was Pozen’s Senior Vice President Finance of from June 2015 through December 31, 2016. Prior to joining Pozen, Mr. Charles served as the Vice President of Finance and Treasurer at Ikaria, Inc., a critical care pharmaceutical company from April 2008 to June 2015. From April 2002 to March 2008, Mr. Charles worked at Reliant Pharmaceuticals, Inc. in various finance functions, culminating with serving as the Vice President of Finance and Treasurer from April 2006 to March 2008. Prior to that, he was a Manager of Assurance and Business Advisory Services at Arthur Andersen, LLP. He holds a BS degree in Business Administration from Bucknell University and is a Certified Public Accountant.

Aralez Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (6.75) % which means that it has lost $6.75 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (262.08) %, meaning that it created substantial loss on money invested by shareholders. Aralez Pharmaceuticals' management efficiency ratios could be used to measure how well Aralez Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 274.57 M in liabilities. Aralez Pharmaceuticals has a current ratio of 0.78, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aralez Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aralez Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aralez Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aralez to invest in growth at high rates of return. When we think about Aralez Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Michael GeraghtySensient Technologies
62
Kevin ThomsonBarrick Gold Corp
67
Sean MoriartyStepan Company
51
Sean LannonAxalta Coating Systems
45
Robert SloneStepan Company
45
Robert FerrisAxalta Coating Systems
N/A
Norman PitcherEldorado Gold Corp
N/A
Michael CashAxalta Coating Systems
56
John CollopySensient Technologies
45
Andor LipsEldorado Gold Corp
N/A
Robert KrcmarovBarrick Gold Corp
55
Jennifer HaleStepan Company
56
Robert WilkinsSensient Technologies
60
Brent JewellApogee Enterprises
49
Tobin TornehlSensient Technologies
50
Greg WalkerBarrick Gold Corp
59
Darian RichBarrick Gold Corp
63
Frank PacholecStepan Company
62
Troy JohnsonApogee Enterprises
50
Kimberly ChaseSensient Technologies
48
Jane BoyceApogee Enterprises
N/A
Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. The company was incorporated in 2015 and is headquartered in Mississauga, Canada. Aralez Pharmaceuticals operates under Drug Manufacturers - Specialty Generic classification in USA and traded on NASDAQ. It employs 164 people. Aralez Pharmaceuticals (ARLZ) is traded on NASDAQ Exchange in USA and employs 164 people.

Management Performance

Aralez Pharmaceuticals Leadership Team

Elected by the shareholders, the Aralez Pharmaceuticals' board of directors comprises two types of representatives: Aralez Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aralez. The board's role is to monitor Aralez Pharmaceuticals' management team and ensure that shareholders' interests are well served. Aralez Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aralez Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Martin Thrasher, Independent Director
Jason Aryeh, Independent Director
Arthur Kirsch, Independent Chairman of the Board
Jennifer Armstrong, Executive Vice President - Human Resources and Administration
Neal Fowler, Independent Director
James Tursi, Chief Medical Officer
Seth Rudnick, Independent Director
Scott Charles, CFO, Senior Vice President
Mark Glickman, Chief Commercial Officer
Robert Harris, Independent Director
Eric Trachtenberg, Chief Compliance Officer, General Counsel, Corporate Secretary
Kenneth Lee, Lead Independent Director
Andrew Koven, President Chief Business Officer
Adrian Adams, CEO, Director
Michael Kaseta, Head of Finance and Interim CFO, Principal Financial Officer, Principal Accounting Officer

Aralez Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aralez Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aralez Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aralez Pharmaceuticals' short interest history, or implied volatility extrapolated from Aralez Pharmaceuticals options trading.

Pair Trading with Aralez Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aralez Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aralez Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to XL Fleet could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace XL Fleet when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back XL Fleet - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling XL Fleet Corp to buy it.
The correlation of XL Fleet is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as XL Fleet moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if XL Fleet Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for XL Fleet can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Other Consideration for investing in Aralez Stock

If you are still planning to invest in Aralez Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aralez Pharmaceuticals' history and understand the potential risks before investing.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing